Clinical Trials Directory

Trials / Unknown

UnknownNCT01540019

Paullinia Cupana for Anorexia in Oncologic Patients

Guarana (Paullinia Cupana) for Anorexia Related to Cancer

Status
Unknown
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
35 (estimated)
Sponsor
Faculdade de Medicina do ABC · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Denutrition, lost of weight and anorexia are present in many oncologic patients at any time of the disease. Anorexia is the spontaneous loss of appetite and many changes in the metabolism are made in this case, leading to this syndrome called anorexia-cachexia, that includes changes in the tumoral response and inflammatory pathways. The guaraná (Paullinia cupana) is originally from Brazil and Venezuela and has been used culturally for headaches, muscle pains, depression and others. As it has shown a good response and tolerability for fatigue, the investigators decide to try guaraná for anorexia. Patients will receive guaraná as capsules of 50 mg twice daily, for 4 weeks, and will be weighted and respond questionaries about quality of life.

Detailed description

Patients 18 years and older, diagnosed with any cancer, that is losing weight and have anorexia will be selected. They must have normal levels of creatinine, thyroid evaluation and hepatic function. If they are taking corticosteroid, they must keep losing weight and refer anorexia, as well as if they are on treatment with chemotherapy. Patients will receive 50mg of the guaraná twice daily for 4 weeks. Every week will be an evaluation of the weight, level of appetite and answer 2 questionaries of quality of life and level of symptoms (FACT-G and MDASI). This is a fase II study, open-label, no randomized, with two steps following ¨two stages of Simon¨ model. First step 18 patients will be included and if there are 3 good responses second step will follow, including 17 more patients. Response will be considered if there is at least 5% of gain in the weight.

Conditions

Interventions

TypeNameDescription
DRUGPaullinia cupana50mg of Paullinia cupana as capsule, twice daily

Timeline

Start date
2011-04-01
Primary completion
2013-07-01
Completion
2013-07-01
First posted
2012-02-28
Last updated
2012-02-28

Locations

1 site across 1 country: Brazil

Source: ClinicalTrials.gov record NCT01540019. Inclusion in this directory is not an endorsement.